The article presents some of the reasons making the new clinical trials of a vaccine candidate based on protein OspA to be confined only in Europe. First, Lyme disease is a non-communicable, readily treatable with common antibiotics and geographically localized in the United States. Second, the European experience with the widely used tick-borne encephalitis vaccine-trial recruitment and greater public acceptance of a new Lyme vaccine.